Merck has announced positive top-line results from a Phase 3 trial of its investigational anti-TL1A monoclonal antibody tulisokibart (MK-7240) in patients with moderately to severely active ulcerative colitis, meeting its primary endpoint of clinical remission at week 12 and key secondary endpoints, with no major safety concerns reported.
The ATLAS-UC induction-only study represents the first time an anti-TL1A antibody has shown clinical remission at 12 weeks in this patient population, reinforcing tulisokibart's potential to address immuno‑fibrosis in inflammatory bowel disease.
Analysts remain cautious about tulisokibart's commercial prospects due to the lack of detailed data and the competitive landscape, including Roche's previously challenged etrolizumab program and other marketed IBD therapies.
Sources:
Merck Expands Tulisokibart Clinical Development Program With ...
Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study
Hits, but mostly misses for Roche's 4 late-stage trials of GI drug ...
Merck reports positive Phase 3 tulisokibart results
Merck & Co., Inc. (MRK) FDA Approvals - MarketBeat
Roche's ulcerative colitis drug etrolizumab looks shaky after data roll ...
Merck's Tulisokibart Hits Key Goals in Phase 3 Ulcerative Colitis Study
Merck anti-TL1A antibody from Prometheus buy passes ph. 3 test
Roche's bowel disease drug shows mixed results in 4 late-stage studies
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in ...
Merck's bowel disease drug meets main goal in late-stage trial
Merck posts 'encouraging' Phase 3 ulcerative colitis data but Roche ...
Extension Study of Long-term Safety and Efficacy of Tulisokibart in ...
MK-7240 for Ulcerative Colitis · Info for Participants - Clinical Trials
Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months ...